

METHOD FOR QUANTIFYING THE LEVEL OF MINIMAL RESIDUAL DISEASE IN A SUBJECT

THE PROBLEM

- MRD refers to the cancer and/or leukemia that remain in a subject during or after treatment of said cancer and/or leukemia by, for example, chemotherapy.
- In particular, it is especially beneficial to monitor the level of minimal residual disease (MRD) in subjects who have been treated for a disease. MRD is the name given to the disease that remains in a subject or a particular tissue thereof during or after treatment of said disease.
- Even there are different approaches for detecting MRD wherein improvements in are achieved through different methods of sequencing, none of the said methods specifically discloses a method which achieves improvement through the alignment strategy used.

INNOVATION SOLUTION

The present invention is focused on a method and kit for quantifying the level of minimal residual disease in a subject. In addition, the present invention is focussed on use of the method and/or kit for quantifying the level of minimal residual disease in a subject.

APPLICANTS

- ✓ FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL 12 DE OCTUBRE (50%)
- ✓ CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES NEURODEGENERATIVAS (CIBERNED) (50%)

IPR STATUS

European Patent Application EP 14191967.0

USA Patent Application 14932267

Further details

INNOVATION UNIT i+12

innovacion.imas12@h12o.es

Instituto de Investigación Hospital 12 de Octubre (i+12)

TLF: 91 7792628 / 917792687

